Felipe
Villacampa Aubá
Consultor Médico
Universitat Pompeu Fabra
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Pompeu Fabra (3)
2022
2019
-
CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402
2015
-
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576